Treatment of inflammatory bowel disease (IBD) (Q26853183)

inflammatory bowel diseases

main subject

0 references

inflammation

0 references

author name string

Pithadia AB

series ordinal

1

1 reference

Jain S

series ordinal

2

1 reference

language of work or name

1 reference

2011

1 reference

published in

Pharmacological Reports

1 reference

volume

63

1 reference

issue

3

1 reference

page(s)

629-42

1 reference

Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Preliminary study of ciprofloxacin in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Protective effects of M40403, a superoxide dismutase mimetic, in a rodent model of colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU)

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Inflammatory bowel disease: etiology and pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Oxidants and free radicals in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

A pilot trial of Saccharomyces boulardii in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Medical therapy of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Probiotic effects of Lactobacillus casei on DSS-induced ulcerative colitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Oral Budesonide in the Management of Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Probiotics (VSL#3) in arthralgia in patients with ulcerative colitis and Crohn's disease: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Cyclosporine in severe ulcerative colitis refractory to steroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Mucosal bacteria in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Double blind, placebo controlled trial of metronidazole in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Inhibition of cytokine-induced nitric oxide synthase expression by gene transfer of adenoviral I kappa B alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2811%2970575-8

7 January 2021